Silvio Traversa
Technik-/Wissenschafts-/F&E-Leiter bei SIENNA BIOPHARMACEUTICALS, INC.
Aktive Positionen von Silvio Traversa
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2016 | - |
Karriereverlauf von Silvio Traversa
Ehemalige bekannte Positionen von Silvio Traversa
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2007 | 01.12.2016 |
| Corporate Officer/Principal | 01.02.2005 | 01.10.2007 | |
| Industria Farmaceutica Serono SpA | Corporate Officer/Principal | - | - |
Ausbildung von Silvio Traversa
| University of Turin | Doctorate Degree |
| Harvard Business School | Graduate Degree |
Statistik
International
| Italien | 4 |
| Vereinigte Staaten | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
| Industria Farmaceutica Serono SpA |
- Börse
- Insiders
- Silvio Traversa
- Erfahrung
